425: Chain Bridge I to Merge with Phytanix Bio, Creating Publicly Traded Cannabinoid Therapeutics Company

Chain Bridge I (CBRG) will merge with Phytanix Bio, a pharmaceutical company focused on cannabinoid-based medicines, with the combined entity expected to trade on Nasdaq under the ticker PHYX.

Summary

• Chain Bridge I (CBRG) and Phytanix Bio have entered into a definitive business combination agreement.
• The combined company, named Phytanix Inc., will focus on developing cannabinoid and cannabinoid-like medicines.
• The transaction values Phytanix Bio at $58 million, plus the assumption of $17 million in preferred stock and $4.4 million in short-term debt.
• The short-term debt will be exchanged for convertible preferred stock at deal close.
• The transaction is expected to close in the fourth quarter of 2024, with the combined company listing on the Nasdaq Capital Market under the ticker symbol PHYX.
• Phytanix Bio's founders, including former GW Pharmaceuticals executives, will lead the new company.
• The company's lead product candidates target treatment-resistant facial seizures and Painful Bladder Syndrome.
• Assuming no redemptions, Phytanix expects to receive up to $11 million of cash held in CBRG's trust account.
• The business combination is not subject to a minimum cash condition.
• The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the experience of the management team, the potential of the company's technology, and the expected benefits of the transaction. The mention of a $7.2 billion acquisition of GW Pharmaceuticals adds to the positive sentiment.

Positives

• Experienced management team with a track record at GW Pharmaceuticals.
• Innovative approach to developing cannabinoid-based medicines.
• Targeting unmet medical needs with lead product candidates.
• Potential access to capital to advance clinical trials.
• The business combination is not subject to a minimum cash condition.

Risks

• The transaction is subject to shareholder approval and other customary closing conditions.
• The company is in the preclinical stage and faces risks associated with drug development and regulatory approval.
• The company may need to raise additional capital to fund its operations.
• The company is subject to competition in the cannabinoid-based medicine market.
• The company is subject to the risks and uncertainties set forth in CBRGs Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q, and other documents filed, or to be filed, with the SEC by CBRG or HoldCo.

Future Outlook

The combined company will focus on advancing its lead product candidates into clinical trials and developing a new generation of medicines made from cannabinoid and cannabinoid-like molecules.

Management Comments

• Barrett Evans, CEO of Phytanix, stated that the company has the necessary IP, scientific acumen, expertise, and management experience to create a new generation of medicines.
• Andrew Cohen, CEO of CBRG, expressed delight in merging with Phytanix Bio, citing the team's depth of experience in developing life-changing cannabinoid and cannabinoid-like medicines.

Industry Context

The announcement comes amid growing interest in cannabinoid-based therapeutics and the potential for these molecules to address unmet medical needs. The merger provides Phytanix Bio with access to public markets and capital to advance its pipeline.

Comparison to Industry Standards

• The press release mentions GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals for $7.2 billion, as a point of reference for the management team's experience.
• This suggests that the combined company aims to replicate the success of GW Pharmaceuticals in developing and commercializing cannabinoid-based medicines.
• The $58 million valuation of Phytanix Bio is relatively small compared to other publicly traded cannabinoid companies, but the company is in the early stages of development.

Stakeholder Impact

• Shareholders of CBRG will have the opportunity to participate in a new company focused on cannabinoid-based medicines.
• Shareholders of Phytanix Bio will gain access to public markets and capital to advance their pipeline.
• Patients with treatment-resistant facial seizures and Painful Bladder Syndrome may benefit from the development of new therapies.

Next Steps

• CBRG will file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus.
• CBRG will mail a final prospectus and definitive proxy statement to shareholders.
• CBRG and Phytanix Bio shareholders will vote on the proposed transaction.
• The transaction is expected to close in the fourth quarter of 2024.

Key Dates

Keywords

Phytanix Bio, Chain Bridge I, cannabinoid, pharmaceutical, merger, acquisition, therapeutics, Nasdaq, biotech, healthcare